This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label
clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20%
administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The
study population will consist of subjects being discharged after hospitalization for acute
decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring
diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or
during hospitalization but without ACLF at discharge.
Decompensated Cirrhosis and Ascites
Standard Medical Treatment,
Albutein 20% Injectable Solution
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.